Vertex Pharmaceuticals share price logo

Vertex Pharmaceuticals

NASDAQ: VRTX

Large Cap

$519.16

+3.72

(+0.72%)

Live

as on

Vertex Pharmaceuticals Stock Performance

as on September 15, 2026 at 3:10 am IST

  • Day's Low

    Day's High

    $514.65
    $525.29
    downward going graph

    0.87%

    Downside

    1.18%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $374.17
    $560.25
    downward going graph

    27.93%

    Downside

    7.91%

    Upside

    downward going graph

Vertex Pharmaceuticals share price movements today

Previous Close
$515.44
Open
$522.17
Volume
163.9K
Market Cap
$130.6B
Day's Low - High
$514.65 - $525.29
52 Week Low - High
$374.17 - $560.25

Vertex Pharmaceuticals Historical Returns

1 Month Return
+ 1.92 %
3 Month Return
+ 15.85 %
1 Year Return
+ 30.65 %
3 Year Return
+ 47.52 %
5 Year Return
+ 173.57 %

Vertex Pharmaceuticals Stock Fundamentals & Key Indicators

Check Vertex Pharmaceuticals market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$130.6B

EPS (TTM)

17.32

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.08%

PE Ratio (TTM)

29.76

Industry PE ratio

10.26

PEG Ratio

1.3232823507197111

EBITDA

5.4B

Revenue (TTM)

12.6B

Profit Margin

86.04%

Return On Equity TTM

23.31%

Vertex Pharmaceuticals Stock Valuation

Track how Vertex Pharmaceuticals P/E has moved over time to understand its valuation trends.

Vertex Pharmaceuticals in the last 5 years

  • Overview

  • Trends

Lowest (-193.61x)

December 31, 2024

Industry (10.26x)

December 31, 2025

Today (29.32x)

December 31, 2025

Highest (29.32x)

December 31, 2025

LowHigh

Today’s Price to Earnings Ratio: 29.32x

Vertex Pharmaceuticals vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Vertex Pharmaceuticals with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
BUY$130.6B173.57%29.7686.04%NA
Revolution Medicines image
Revolution Medicines
BUY$44.6B614.61%NA0.00%NA
Moderna image
Moderna
BUY$57.5B-66.34%-18.04-12.57%NA
Regeneron image
Regeneron
BUY$80.5B21.13%18.6684.86%47.339999999999996%

Stock Returns calculator for Vertex Pharmaceuticals Stock including INR - Dollar returns

The Vertex Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Vertex Pharmaceuticals investment value today

Current value as on today

₹1,42,667

Returns

₹42,667

(+42.67%)

Returns from Vertex Pharmaceuticals Stock

₹31,589 (+31.59%)

Dollar Impact

₹11,077 (+11.08%)

Analyst Recommendation on Vertex Pharmaceuticals Stock

Based on 26 analysts

BUY

80.77%

Buy

15.38%

Hold

3.85%

Sell

Based on 26 analysts, 80.76923076923077% of analysts recommend a 'BUY' rating for Vertex Pharmaceuticals. Average target price of $569.19

Vertex Pharmaceuticals Share Price Target

Get share price movements and forecasts by analysts on Vertex Pharmaceuticals.

What analysts predicted

8.79%UPSIDE

Target Price

$569.19

Current Price

$519.16

Analyzed by

26 Analysts

Target

$569.19

Vertex Pharmaceuticals target price $569.19, a slight upside of 8.79% compared to current price of $519.16. According to 26 analysts rating.

Indian Investors' Interest in Vertex Pharmaceuticals Stock

Investment in Vertex Pharmaceuticals Shares on INDmoney has dropped by -5.76% in the last 30 days, indicating reduced investment activity.

Time period: to

Change:-5.76% versus previous 30 day period

Search interest for Vertex Pharmaceuticals Stock has decreased by -17% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-17% versus previous 30 day period

Vertex Pharmaceuticals Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
2,687
2,645
2,771
2,912
2,770
2,964
3,076
3,227
2,986
3,333
Gross Profit
2,344
2,273
2,379
2,488
2,407
2,557
2,661
2,761
2,594
2,844
Operating Income
1,139
-3,514
1,116
1,026
630
1,151
1,186
1,300
1,138
1,247
EBITDA
1,343
-3,327
1,284
1,184
781
1,338
1,356
1,387
1,308
1,392
Interest Expense
10
9
7
2
3
3
3
3
-
-
Depreciation
53
54
53
46
48
51
54
53
55
-
Income Before Tax
1,279
-3,391
1,224
1,136
730
1,283
1,298
1,331
1,252
1,392
Income Tax Expense
179
202
178
223
84
250
215
139
221
292
Net Income
1,099
-3,593
1,045
913
646
1,032
1,082
1,191
1,031
1,099
Net Profit Margin
87.25%
85.94%
85.84%
85.46%
86.90%
86.25%
86.52%
85.56%
86.85%
85.33%

Vertex Pharmaceuticals Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
2,488
3,047
4,162
6,205
7,574
8,930
9,869
11,020
12,074
Gross Profit
2,213
2,638
3,615
5,469
6,670
7,850
8,607
9,489
10,267
Operating Income
123
635
1,197
2,856
2,782
4,307
3,832
-232
4,760
EBITDA
103
706
1,560
3,284
2,917
4,435
4,605
486
4,863
Interest Expense
69
34
58
58
61
54
44
30
13
Depreciation
61
72
106
109
125
148
181
205
207
Income Before Tax
-15
600
1,394
3,116
2,730
4,232
4,379
248
4,643
Income Tax Expense
-107
-1,486
218
405
388
910
760
784
690
Net Income
263
2,096
1,176
2,711
2,342
3,322
3,619
-535
3,953
Net Profit Margin
88.95%
86.56%
86.84%
88.14%
88.06%
87.90%
87.21%
86.11%
85.03%

Vertex Pharmaceuticals Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
1,099
-3,593
1,045
913
646
1,032
1,082
1,191
1,031
1,099
Operating Cash Flow
1,306
-3,753
1,369
584
818
1,073
1,241
498
1,428
1,125
Investing Cash Flow
-2,136
-463
-348
-821
-55
-484
-117
-288
-431
-45
Financing Cash Flow
-357
-358
-387
-391
-680
-349
-1,154
-77
-538
-426
Change in Cash
-1,202
-4,578
657
-675
113
296
-34
140
417
649

Vertex Pharmaceuticals Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
91
2,087
1,176
2,711
2,342
3,322
3,619
-535
3,953
Operating Cash Flow
844
1,270
1,569
3,253
2,643
4,129
3,537
-492
3,631
Investing Cash Flow
-437
-202
-1,235
99
-340
-321
-3,141
-3,770
-945
Financing Cash Flow
68
-71
126
-505
-1,478
-67
-562
-1,494
-2,261
Change in Cash
481
990
462
2,868
811
3,711
-139
-5,800
515

Mutual Funds that own Vertex Pharmaceuticals Stock

Check out the Mutual Funds with significant holdings in Vertex Pharmaceuticals.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
6.94835%
17611352
Growth Fund of America
5.431626%
13767050
Investment Co of America
2.473415%
6269142
American Balanced Fund
2.339973%
5930918
AMCAP Fund
1.823266%
4621267
See all

Global Institutional Holdings in Vertex Pharmaceuticals

Funds
Holdings
Vanguard
8.11%
iShares
6.39%
SPDR
4.04%
Invesco
3.86%
JPMorgan
1.26%
See all

Vertex Pharmaceuticals News & Key Events

  • img

    Today's Timeline - 14 September

    Mon, 06:11 PM

    -

    Vertex advances diversified pipeline with global CF launches and renal expansion, pivotal readouts for pove and inaxaplin upcoming.

Insights on Vertex Pharmaceuticals

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Vertex Pharmaceuticals has shown positive profit trends over the past two quarters. The company's net profit increased from $1.03 billion to $1.09 billion, reflecting an average growth of 6.2% each quarter.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Vertex Pharmaceuticals has shown positive revenue growth over the past two quarters. Revenue increased from $2.98 billion to $3.33 billion, reflecting an average growth of 10.4% per quarter.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, VRTX stock has moved up by 15.8%

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, VRTX has outperformed top 5 stocks with highest market-cap in its industry

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 512.4% return, outperforming this stock by 481.8%

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
OrganisationVertex Pharmaceuticals
Headquarters50 Northern Avenue, Boston, MA, United States, 02210
IndustryBiotechnology
CEODr. Reshma Kewalramani FASN, M.D.
E-voting on sharesClick here to vote

Key Management of Vertex Pharmaceuticals

Name

Title

Dr. Mark Bunnage D.Phil

Executive VP & Chief Scientific Officer

Ms. Susie Lisa C.F.A.

Senior Vice President of Investor Relations

Ms. Joy Liu J.D.

EVP, Chief Legal Officer & Corporate Secretary

Dr. Reshma Kewalramani FASN, M.D.

CEO, President & Director

Mr. Charles F. Wagner Jr.

Executive VP, COO & CFO

Mr. Amit K. Sachdev J.D.

Executive VP & Chief Patient and External Affairs Officer

Dr. Carmen Bozic M.D.

Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer

Dr. Jeffrey Marc Leiden M.D., Ph.D.

Executive Chairman

Dr. Ourania Tatsis Ph.D.

Executive VP & Chief Product Affairs Officer

Ms. Kristen C. Ambrose CPA

Senior VP & Chief Accounting Officer

FAQs

What is Vertex Pharmaceuticals share price today?

Vertex Pharmaceuticals share price today is $519.16 as on . Vertex Pharmaceuticals share today touched a day high of $525.29 and a low of $514.65.

What is the 52 week high and 52 week low for Vertex Pharmaceuticals share?

Vertex Pharmaceuticals share touched a 52 week high of $560.25 on and a 52 week low of $374.17 on . Vertex Pharmaceuticals stock price today i.e. is trending at $519.16,which is 7.33% down from its 52 week high and 38.75% up from its 52 week low.

What is Vertex Pharmaceuticals's market capitalisation today?

Vertex Pharmaceuticals market capitalisation is $0.13T as on .

How to invest in Vertex Pharmaceuticals Stock (VRTX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Vertex Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Vertex Pharmaceuticals Shares that will get you 0.0029 shares as per Vertex Pharmaceuticals share price of $519.16 per share as on September 14, 2026 at 9:40 pm IST.

What is the minimum amount required to buy Vertex Pharmaceuticals Stock (VRTX) from India?

Indian investors can start investing in Vertex Pharmaceuticals (VRTX) shares with as little as ₹95.54 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹955.40 in Vertex Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on ). Based on Vertex Pharmaceuticals share’s latest price of $519.16 as on September 14, 2026 at 9:40 pm IST, you will get 0.0193 shares of Vertex Pharmaceuticals. Learn more about fractional shares .

What are the returns that Vertex Pharmaceuticals has given to Indian investors in the last 5 years?

Vertex Pharmaceuticals stock has given 173.57% share price returns and 29.75% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?